

# Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension

Technology Guidance from the MOH Drug Advisory Committee

## Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Brinzolamide 1% eye drops; and
- ✓ Brinzolamide/timolol 1%/0.5% eye drops

in line with their registered indications for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension, in view of acceptable price proposals from the manufacturer.

### Subsidy status

Brinzolamide 1% and brinzolamide/timolol 1%/0.5% eye drops are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

SDL subsidy **does not** apply to brinzolamide/brimonidine 1%/0.2% eye drops in view of unacceptable price proposal from the manufacturer.

### **About the Agency**

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government subsidy decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

This guidance is based on the evidence available to the MOH Drug Advisory Committee as at 26 November 2021. It is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

*Find out more about ACE at [www.ace-hta.gov.sg/about](http://www.ace-hta.gov.sg/about)*

### **© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore**

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Chief HTA Officer  
Agency for Care Effectiveness  
Email: [ACE\\_HTA@moh.gov.sg](mailto:ACE_HTA@moh.gov.sg)

In citation, please credit the "Ministry of Health, Singapore" when you extract and use the information or data from the publication.